Tinurilimab

替奴瑞利单抗

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTinurilimab
Drug Alias NameCancer immunotherapie -Bayer/German Cancer Research CenterBAY-1834942
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 6 inhibitors
TargetsCarcinoembryonic antigen related cell adhesion molecule 6
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGerman Cancer Research Center (Dkfz)Bayer AG
China Registration ClassN/A

Develop Information

Active CompaniesGerman Cancer Research Center (Dkfz)Bayer AG
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A